Perrin A, Milano G, Thyss A, Cambon P, Schneider M
Centre Antoine Lacassagne, Nice, France.
Br J Cancer. 1990 Nov;62(5):736-41. doi: 10.1038/bjc.1990.369.
Severe methotrexate (MTX) toxicity is a proven complication of associations of MTX and non-steroidal anti-inflammatory drugs (NSAIDs). This study investigated the interaction between MTX (50 or 100 mg kg-1) and ketoprofen (KP) (3 mg kg-1 day-1, pretreatment for 8 days) in the rabbit. The drug association induced a reversible increase in blood urea and creatinine. The severity degree of renal dysfunction was significantly related to the MTX dose; it was not modified by prolonged exposure to KP after MTX administration. The biological markers of haematopoietic and hepatic functions were unchanged. Pretreatment by KP induced a marked reduction (70%) in the urinary excretion of the prostaglandin 6-keto-PGF1 alpha. MTX dose-related alterations in MTX pharmacokinetics were also observed with the drug association: at a MTX dose of 100 mg kg-1, the presence of KP significantly reduced the total body clearance, the renal clearance and the fraction of MTX eliminated in urine as compared to controls. An appreciable reduction in the plasma binding of MTX was also noted in vivo when KP was associated. This experimental study confirms the existence of an interaction between MTX and KP and demonstrates its renal origin.
严重甲氨蝶呤(MTX)毒性是MTX与非甾体抗炎药(NSAIDs)联用的一种已证实的并发症。本研究调查了兔体内MTX(50或100 mg kg-1)与酮洛芬(KP)(3 mg kg-1 天-1,预处理8天)之间的相互作用。药物联用导致血尿素和肌酐可逆性升高。肾功能障碍的严重程度与MTX剂量显著相关;MTX给药后长期暴露于KP并未改变其严重程度。造血和肝功能的生物标志物未发生变化。KP预处理导致前列腺素6-酮-PGF1α的尿排泄显著减少(70%)。药物联用还观察到MTX药代动力学的剂量相关改变:与对照组相比,在MTX剂量为100 mg kg-1时,KP的存在显著降低了全身清除率、肾清除率以及尿中MTX的消除分数。当联用KP时,还在体内观察到MTX血浆结合率明显降低。本实验研究证实了MTX与KP之间存在相互作用,并证明了其源于肾脏。